Complexities of personalized medicine: How genes, drug-drug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug's effect

Journal of Psychiatric Practice

Volumn 19, Issue 5, 2013, Pages 397-405

  Preskorn, Sheldon H ^a,b,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b WICHITA STATE UNIVERSITY   (United States)

^c LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

Author keywords

Cytochrome P450 enzymes; Drug drug interactions; Genetic polymorphism; hERG; Iloperidone; Personalized medicine; Pharmacodynamics; Pharmacokinetics; QTc interval

Indexed keywords

CLARITHROMYCIN; ILOPERIDONE; KETOCONAZOLE; METFORMIN; PAROXETINE; POTASSIUM CHANNEL HERG; QUETIAPINE; ZIPRASIDONE;

ADVERSE OUTCOME; AGED; ANTIBIOTIC THERAPY; BINDING AFFINITY; BRONCHITIS; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG WITHDRAWAL; FAINTNESS; FOLLOW UP; GENE INTERACTION; GENOTYPE; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MALE; MOLECULAR BIOLOGY; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TORSADE DES POINTES; TREATMENT DURATION;

AFFECTIVE DISORDERS, PSYCHOTIC; AGED; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DIZZINESS; DRUG INTERACTIONS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INDIVIDUALIZED MEDICINE; ISOXAZOLES; MALE; PAROXETINE; PHARMACOGENETICS; PIPERIDINES;

EID: 84885003736     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000435038.91049.cb     Document Type: Review

References (23)

1. Lubke GH, Hottenga JJ, Walters R, et al. Estimating the genetic variance of major depressive disorder due to all single nucleotide polymorphisms. Biol Psychiatry 2012 72:707-9.
2. Tansey KE, Guipponi M, Hu X et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013;73:679-82
3. Lee SH, Ripke SS, Neale BM, et al. Genetic relationship between five psychiatric disorders estimated from genomewide SNPs. Nature Genetics 2013;45:984-94.
4. Potkin S, Preskorn S, Hochfeld M, et al. Thorough QTc study of iloperidone at three different doses with and without CYP 2D6 and/or 3A4 inhibition in comparison to quetiapine and ziprasidone. J Clin Psychopharmacol 2013;33: 3-10.
5. Preskorn S. Patients who do not respond to the usual dose: Why Terry fell off the dose-response curve. J Psychiatr Pract 2009;15:460-6.
6. Preskorn S, Hatt C. How pharmacogenomics (PG) are changing practice: Implications for prescribers, their patients, and the healthcare system (PG Series Part I). J Psychiatr Pract 2013;19:142-9.
7. Preskorn S. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003;9:150-8.
8. Preskorn S. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003;9:228-36.
9. Novartis Pharmaceuticals Corporation. Fanapt (iloperidone) package insert, January 2013 (available at www.pharma.us.novartis.com/product/pi/pdf/ fanapt.pdf, accessed September 3, 2013).
10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Iloperidone pharmacology review, 2007 (available at www.accessdata.fda.gov /drugsatfda-ocs/nda/2009/022192s000-harmR-1.pdf, accessed September 3, 2013).
11. Preskorn S. Clinical relevance of relative receptor binding affinity: Quetiapine and ziprasidone as examples. J Psychiatr Pract 2007;13:393-8.
12. U.S. National Library of Medicine. Genetics home reference: KCNH2 (available at http://ghr.nlm.nih.gov/gene /KCNH2, accessed September 9, 2013).
13. Tristani-Firouzi M, Sanguinetti MC. Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. J Mol Cell Cardiol 2003;35:27-35.
14. Kaplan W, Sisken J. Genetic and autoradiographic titrated thymidine studies in tests of Drosophila melanogaster. Experientia 1960;16:67-9.
15. Warmke J, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci 1994;91:3438-42.
16. Hedley PL, Jrgensen P, Schlamowitz S, et al. The genetic basis of long QT and short QT syndromes: A mutation update. Hum Mutat 2009;30:1486-511.
17. Preskorn S. Patient with bipolar disorder and familial QT prolongation: What to do? J Psychiatr Pract 2006;12:109-2.
18. Preskorn S. Clinically important differences in the pharmacokinetics of the ten newer atypical antipsychotics: Part 2. Metabolism and elimination. J Psychiatr Pract 2012;18:361-8.
19. Wang D, Guo Y, Wrighton A, et al. Intronic polymorphism in CYP 3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11:274-86.
20. Preskorn S, Kane C, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: Implications for personalized medicine. J Clin Psychiatry 2013;74:614-21.
21. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), October 2005.
22. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
23. Preskorn S: The use of biomarkers in psychiatric research: How serotonin transporter occupancy explains the doseresponse curves of SSRIs. J Psychiatric Practice 2012;18: 38-45.